Edition:
United Kingdom

Rocket Pharmaceuticals Inc (RCKT.OQ)

RCKT.OQ on NASDAQ Stock Exchange Global Market

20.51USD
21 Aug 2018
Change (% chg)

$0.19 (+0.94%)
Prev Close
$20.32
Open
$20.47
Day's High
$20.83
Day's Low
$20.30
Volume
42,382
Avg. Vol
100,377
52-wk High
$24.20
52-wk Low
$3.77

Latest Key Developments (Source: Significant Developments)

Rocket Pharmaceuticals Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing
Monday, 25 Jun 2018 

June 25 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING.  Full Article

Rocket Pharmaceuticals Presents Updated Data From Phase 1/2 Gene Therapy Trial Of Rp-L102
Friday, 18 May 2018 

May 18 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS PRESENTS UPDATED DATA FROM PHASE 1/2 GENE THERAPY TRIAL OF RP-L102 IN PATIENTS WITH FANCONI ANEMIA AT THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) ANNUAL MEETING.ROCKET PHARMACEUTICALS - CONTINUED CLINICAL EVIDENCE DEMONSTRATES RP-L102 CAN RESTORE BONE MARROW FUNCTION OF FANCONI ANEMIA PATIENTS WITHOUT CONDITIONING.ROCKET PHARMACEUTICALS INC - ALL PATIENTS DEMONSTRATED CONTINUED IMPROVEMENT IN ENGRAFTMENT FOLLOWING ADMINISTRATION OF RP-L102 IN TRIAL.ROCKET PHARMACEUTICALS INC - NO SERIOUS DRUG-RELATED ADVERSE EVENTS HAVE BEEN OBSERVED TO DATE IN TRIAL.ROCKET PHARMACEUTICALS INC - ADDITIONAL PATIENT DATA FROM FA PROGRAM IS EXPECTED OVER NEXT 12-18 MONTHS.ROCKET PHARMACEUTICALS - ROCKET WILL ENGAGE WITH REGULATORY AUTHORITIES TO PROGRESS RP-L102 TOWARDS A POTENTIAL GLOBAL REGISTRATIONAL STUDY IN 2019.  Full Article

Rocket Pharmaceuticals Prices Public Offering Of Common Stock
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.50 MILLION COMMON SHARES PRICED AT $13.25PER SHARE.  Full Article

Inotek files for preliminary proxy statement for proposed merger with Rocket Pharmaceuticals
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Inotek Pharmaceuticals Corp :Inotek Pharmaceuticals announces filing of preliminary proxy statement for proposed merger with clinical-stage gene therapy company, Rocket Pharmaceuticals.Inotek Pharmaceuticals Corp - ‍additional first-in-human results from up to three programs expected in 2018​.Inotek Pharmaceuticals Corp - ‍merger is expected to close in Q1 of 2018​.  Full Article

BRIEF-Rocket Pharmaceuticals Reports Full-Year 2017 Results

* ROCKET PHARMACEUTICALS REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS